{"id":"NCT01450761","sponsor":"Bristol-Myers Squibb","briefTitle":"Trial in Extensive-Disease Small Cell Lung Cancer (ED-SCLC) Subjects Comparing Ipilimumab Plus Etoposide and Platinum Therapy to Etoposide and Platinum Therapy Alone","officialTitle":"Randomized, Multicenter, Double-Blind, Phase 3 Trial Comparing the Efficacy of Ipilimumab Plus Etoposide/Platinum Versus Etoposide/Platinum in Subjects With Newly Diagnosed Extensive-Stage Disease Small Cell Lung Cancer (ED-SCLC)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2011-12-13","primaryCompletion":"2015-03-19","completion":"2017-05-17","firstPosted":"2011-10-12","resultsPosted":"2016-07-18","lastUpdate":"2020-07-08"},"enrollment":1351,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Small Cell Lung Carcinoma"],"interventions":[{"type":"BIOLOGICAL","name":"Ipilimumab","otherNames":["Yervoy","BMS-734016"]},{"type":"BIOLOGICAL","name":"Placebo matching Ipilimumab","otherNames":[]},{"type":"DRUG","name":"Etoposide","otherNames":["Etopophos","Neoposid","Eposin"]},{"type":"DRUG","name":"Cisplatin","otherNames":["Platinol"]},{"type":"DRUG","name":"Carboplatin","otherNames":["Paraplatin"]}],"arms":[{"label":"Ipilimumab+Etoposide+Cisplatin/Carboplatin","type":"EXPERIMENTAL"},{"label":"Placebo matching Ipilimumab+Etoposide+Cisplatin/Carboplatin","type":"PLACEBO_COMPARATOR"}],"summary":"The purpose of the study is to determine whether the addition of Ipilimumab to Etoposide and Platinum therapy will extend the lives of patients with Extensive-Stage Disease Small Cell Lung Cancer (ED-SCLC) more than Etoposide and Platinum therapy alone.","primaryOutcome":{"measure":"Overall Survival (OS) in Participants Who Received at Least One Dose of Blinded Study Therapy","timeFrame":"Randomization until date of death, up to March 2015, approximately 38 months","effectByArm":[{"arm":"Ipilimumab and Platinum/Etoposide","deltaMin":10.97,"sd":null},{"arm":"Placebo and Platinum/Etoposide","deltaMin":10.94,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.3775"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":2,"exclusionCount":3},"locations":{"siteCount":225,"countries":["United States","Argentina","Australia","Austria","Belgium","Brazil","Canada","Chile","China","Colombia","Czechia","France","Germany","Hong Kong","Hungary","Ireland","Israel","Italy","Japan","Mexico","Netherlands","Peru","Poland","Portugal","Romania","Russia","South Africa","South Korea","Spain","Sweden","Switzerland","Taiwan","Thailand","United Kingdom"]},"refs":{"pmids":["27458307"],"seeAlso":["https://www.bms.com/researchers-and-partners/clinical-trials-and-research.html","https://www.bmsstudyconnect.com/s/US/English/USenHome","https://www.bms.com/researchers-and-partners/investigator-inquiry-form.html","https://www.fda.gov/Safety/MedWatch/SafetyInformation/default.htm"]},"adverseEventsSummary":{"seriousAny":{"events":316,"n":562},"commonTop":["Neutropenia","Nausea","Alopecia","Anaemia","Fatigue"]}}